Viridian Therapeutics (VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug [VRDN-001] to ...

Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Sarah Jackson Every time Sarah publishes a story, you’ll get an alert straight to your inbox!

Good afternoon Insiders, it’s time for you to get your weekly fix as we dive head first behind the headlines. Please read on, and sign up here. Netflix Dishes The Data Being transparent: Long-serving ...

After two hit films, Ted has returned in his very own TV series on Peacock, and now the foul-mouthed teddy bear is back for a ...